Explore this article's sources with AI
Follow PeptideMethods on Google
PT-141 UK status: what changed
No UK-authorised bremelanotide or Vyleesi product was identified. Here is the product-status boundary and the documented 12-month no-change finding.
Why we wrote this. UK readers need product authorisation, foreign approval and the narrow specials route kept separate, with a dated no-change finding.
In this article (10 sections)
- PT-141, bremelanotide and Vyleesi are different identity layers
- What the MHRA product search means
- The EMA inventory is a separate supporting check
- Unauthorised is not the same as ordinary prescription-only status
- The specials framework is a narrow exception
- Research-use wording does not settle classification
- What changed from 8 November 2025 to 8 November 2026
- The US approval remains jurisdiction-specific
- Who can verify a claimed UK route
- The current status is an authorised-product absence
No PT-141, bremelanotide or Vyleesi finished medicine was identified in the UK product record on 8 November 2026. Exact MHRA Products searches for bremelanotide and Vyleesi returned no results.[1] The current EMA workbook also contained no match for PT-141, PT 141, bremelanotide or Vyleesi.[2] The current finding is absence of an identified authorised product under the names checked.
That result does not support a one-word claim that every material called PT-141 is legal or illegal. Product classification, sale, import and possession are different questions. The item, its presentation, intended use and supply route matter. It does support a clear ordinary-market conclusion: no named UK-licensed PT-141 or Vyleesi product was found.
PT-141, bremelanotide and Vyleesi are different identity layers
PubChem records PT-141 as a name associated with bremelanotide.[3] DailyMed identifies Vyleesi as a specific US prescription injection containing 1.75 mg bremelanotide in a single-dose autoinjector.[4] The US label belongs to that manufacturer, formulation and pack. It does not approve unrelated powder vials.
This distinction prevents two common errors. A molecule name is not a finished-product licence, and a foreign finished-product approval does not transfer into the UK. A research vial is a third object unless its identity and regulated supply chain can be demonstrated. Shared wording on a seller page cannot collapse those categories.
What the MHRA product search means
The MHRA Products service explains that UK-authorised medicines carry product-licence identifiers such as PL, PLGB or PLNI numbers. Its exact bremelanotide and Vyleesi searches showed no results on the check date.[1] No licence number, marketing-authorisation holder, strength, dosage form or UK pack was identified.
This is a dated public-record finding. It does not expose confidential applications and cannot rule out a future authorisation or a record under an unknown synonym. We used the molecule and known US brand because those are the identity terms supported by primary records. The absence finding should remain attached to those search terms and date.
The EMA inventory is a separate supporting check
EMA publishes downloadable medicine data for the central European system. Searching the workbook content for PT-141, PT 141, bremelanotide and Vyleesi produced zero matches on 8 November 2026.[2] This establishes only that no matching central record was identified under those names. The MHRA search is the direct national check.
The two sources answer different questions but align on the practical product finding. Neither produced an authorised finished medicine that could be routinely marketed as PT-141 or Vyleesi in the UK. The US DailyMed record is not a contrary UK result. It establishes the US product's identity and jurisdiction.
Unauthorised is not the same as ordinary prescription-only status
Regulation 46 of the Human Medicines Regulations 2012 provides that a person may not sell, supply, or offer to sell or supply an unauthorised medicinal product unless an exemption applies.[5] With no matching UK marketing authorisation identified, PT-141 should not be described as an ordinary licensed prescription medicine in the UK.
Vyleesi is prescription-only in the United States under its US label. That classification does not create a UK licence or routine prescription item. A UK prescription also cannot authenticate an unidentified vial. Product authorisation, prescriber involvement and the dispensing chain must each be established rather than inferred from the molecule name.
The product-record absence does not by itself make simple possession a narcotics offence. None of the primary sources used here classifies bremelanotide as a controlled drug. Sale, supply, import, administration and possession have distinct legal tests. This page avoids extending the authorisation finding beyond what the records prove.
The specials framework is a narrow exception
MHRA guidance defines specials as unlicensed products specially manufactured or imported for an individual patient's treatment after an order by an authorised prescriber.[6] The import guidance requires an appropriate manufacturer or wholesale licence, prior MHRA notification and no agency objection before an unlicensed medicine is imported.[7]
This route does not authorise bremelanotide as a molecule for general sale. It concerns an exact product, patient, prescriber and regulated supply chain. The existence of the framework does not prove that a proposed Vyleesi request would be clinically justified, accepted by the MHRA, dispensed by a pharmacy or funded. It certainly does not cover direct orders from research sellers.
Research-use wording does not settle classification
A website may state that a vial is not for human consumption while surrounding it with effect claims and an injectable presentation. The legal analysis can depend on the actual product and how it is presented. A disclaimer is evidence to consider, not a marketing authorisation or a binding classification decision. A genuine analytical reference material supplied for laboratory work presents different facts from a consumer injection product.
This is why the article does not claim that the word PT-141 always produces one status. The named finished-product record is absent. An actual vial may still be assessed as an unauthorised medicinal product based on its composition, claims and intended function. The MHRA is the authority to ask about a particular product.
What changed from 8 November 2025 to 8 November 2026
We checked the current MHRA product results, current EMA workbook, Human Medicines Regulations and MHRA unlicensed-supply guidance for the 12-month period. We identified no PT-141, bremelanotide or Vyleesi UK approval, refusal, withdrawal or product-specific classification decision during that period. The named finished-product status did not change in the public records reviewed.
The MHRA import and specials pages were updated in January 2025, before this comparison window. Their current text continues to describe licensed importers, prior notification and patient-specific specials. A new clinical trial, seller launch or US commercial development would not by itself be a UK regulatory change. A change needs a UK product record, formal decision or applicable legal amendment.
The US approval remains jurisdiction-specific
DailyMed's Vyleesi record identifies the regulated US autoinjector, labelled population and product warnings.[4] It is not evidence of UK approval, NHS reimbursement or routine pharmacy availability. The UK and United States maintain separate authorisation systems.
The label also cannot verify a seller's vial. An ingredient name does not establish dosage form, manufacturer, strength, sterility or regulated release. A certificate of analysis may report one submitted sample without linking it to every shipped unit. Neither document creates a UK marketing authorisation.
Who can verify a claimed UK route
Ask the MHRA about the exact product's classification and authorisation status. Provide the manufacturer, dosage form, strength, label, claims and source country. A registered pharmacy can verify whether an identifiable finished product and patient-specific route exist. If import is proposed, the licensed importer should be named and the MHRA notification should be documented.
For wider context, read the UK regulation hub and the PT-141 evidence overview. Neither page substitutes for checking the physical product and proposed supply chain.
The current status is an authorised-product absence
As of 8 November 2026, no bremelanotide or Vyleesi product was identified in the MHRA service and no matching central EMA record appeared under the identity terms checked. No product-specific UK change was found in the prior 12 months. Exceptional supply and the status of a physical vial require separate, product-specific assessment.
Medical disclaimer: This article is for educational and journalistic purposes only and does not constitute medical advice. Peptides discussed may be classified as prescription medicines or research chemicals depending on your jurisdiction. Always consult a qualified healthcare professional before using any peptide product. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product.
Regulatory disclaimer: This page reflects our understanding of the regulatory status as of 8 November 2026. Regulations change. Verify with the official regulator before making any decision. PeptideMethods.com is not a law firm and does not provide legal advice.
Frequently asked
Is PT-141 approved in the UK?
No bremelanotide or Vyleesi product was identified in exact MHRA searches on 8 November 2026, and no matching central EMA record was found under PT-141, bremelanotide or Vyleesi.
Is PT-141 a prescription-only medicine in the UK?
No ordinary licensed UK product was identified, so prescription-only is incomplete. Vyleesi is a US prescription product, but its US status does not create UK authorisation.
Can bremelanotide be supplied as a UK special?
The specials framework permits patient-specific unlicensed supply under prescriber responsibility through licensed participants. It does not grant general approval or prove that bremelanotide qualifies in an individual case.
Did PT-141's UK status change in the last year?
No UK approval, refusal, withdrawal or product-specific classification decision was identified from 8 November 2025 through 8 November 2026 in the official records reviewed.
Does Vyleesi's US approval apply in the UK?
No. Vyleesi is a specific US prescription autoinjector. Its US approval does not create a UK licence, NHS price or routine pharmacy availability.
Sources
- [1]MHRA Products: exact bremelanotide search returned no results on 8 November 2026Tier 1 · primary↩
- [2]European Medicines Agency: downloadable medicine dataTier 1 · primary↩
- [3]NIH PubChem: Bremelanotide compound record and PT-141 synonymTier 1 · primary↩
- [4]DailyMed: Vyleesi (bremelanotide) US prescribing informationTier 1 · primary↩
- [5]The Human Medicines Regulations 2012, regulation 46Tier 1 · primary↩
- [6]MHRA: Supply unlicensed medicinal products (specials)Tier 1 · primary↩
- [7]MHRA: Import a human medicineTier 1 · primary↩
No revisions yet. First published .